Funding for this research was provided by:
National Institute on Aging (AG051266, AG059695, AG065651)
BrightFocus Foundation (A2015275S)
Alzheimer's Research UK (Senior Fellowship)
Article History
Received: 18 December 2021
Accepted: 21 April 2022
First Online: 1 June 2022
Declarations
:
: All procedures involving human specimens were in accordance with ethical standards of New York University School of Medicine, the Queen Square Brain Bank (QSBB) for Neurological Disorders at UCL, and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All human brain tissue samples were from the QSBB and were donated with full, informed consent. Accompanying clinical and demographic data of all cases used in this study were stored electronically in compliance with the 1998 data protection act. Ethical approval for the study was obtained from the National Health Services (NHS) research ethics committee (NEC) and in accordance with the human tissue authority’s (HTA’s) code of practice and standards under number 12198. Animal studies involving intracerebral injection with the different Aβ preparations were conducted following institutionally approved IACUC protocols in accordance with NIH guidelines.
: Not applicable.
: The authors declare that they have no competing interests.